Patents Represented by Attorney, Agent or Law Firm Ron K. Levy
  • Genes encoding telomerase protein 1
    Patent number: 5919656
    Abstract: Disclosed are nucleic acid molecules encoding polypeptides that specifically bind telomerase RNA. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
    Type: Grant
    Filed: November 15, 1996
    Date of Patent: July 6, 1999
    Assignees: Amgen Canada Inc., Amgen Inc.
    Inventors: Lea Anne Harrington, Murray O. Robinson
  • Method of reconstituting hematopoietic cells using monoclonal antibodies to the stem cell factor receptor
    Patent number: 5906938
    Abstract: The present invention relates to monoclonal antibodies specific for a cell receptor specific for human stem cell factor (hSCF) as well as pharmaceutical compositions containing such monoclonal antibodies and uses of such monoclonal antibodies for the isolation and reconstitution of hematopoietic cells expressing the stem cell factor receptor.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: May 25, 1999
    Assignee: Board of Regents of the University of Washington
    Inventors: Virginia C. Broudy, Nancy Lin
  • Genes encoding LSIRF polypeptides
    Patent number: 5891666
    Abstract: Disclosed are nucleotide sequences encoding a novel polypeptide termed LSIRF. Also disclosed are methods of preparing the polypeptide and uses thereof.
    Type: Grant
    Filed: April 3, 1996
    Date of Patent: April 6, 1999
    Assignee: Amgen Canada Inc.
    Inventors: Toshifumi Matsuyama, Alex Grossman
  • Antibodies which activate an erythropoietin receptor
    Patent number: 5885574
    Abstract: Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.
    Type: Grant
    Filed: July 26, 1994
    Date of Patent: March 23, 1999
    Assignee: Amgen Inc.
    Inventor: Steven G. Elliott
  • Method for reducing carryover contamination in an amplification procedure
    Patent number: 5876976
    Abstract: The present invention provides an efficient and economical method for reducing carryover contamination in an amplification procedure. The method of the present invention enables background caused by contaminant amplification product to be reduced or eliminated through the incorporation of at least one modification into the amplification product. The modified amplification product is readily distinguishable from the target sequence in a test sample. Prior to amplifying the target in a new test sample, the sample may be treated to selectively eliminate the contaminant amplification product so that it cannot be amplified in the new sample.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: March 2, 1999
    Assignee: Amgen Inc.
    Inventors: Rodney M. Richards, Theodore Jones, David L. Snitman, Gregory S. Brown
  • Progenitor B cell stimulating factor
    Patent number: 5874399
    Abstract: A progenitor B cell stimulating factor which promotes the formation of pre-B cells is described. DNA sequences encoding same and methods of production and purification of the factor are also disclosed. The factor is used in the treatment of hematopoietic disorders and in bone marrow transplantation.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: February 23, 1999
    Assignee: Amgen Inc.
    Inventor: Babru Bahan Samal
  • Mutagenized DNA molecules encoding modified subunit a of Cholera-toxin
    Patent number: 5874287
    Abstract: The development of subunits and subunit analogs of the cholera exotoxin by recombinant DNA techniques provides vaccine products that can retain their biological activity and immunogenicity, and can confer protection against disease challenge. Genetically-engineered modifications of the subunits result in products that retain immunogenicity, yet are reduced in, or are essentially free of, enzymatic activity associated with toxin reactogenicity.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: February 23, 1999
    Assignee: Amgen Inc.
    Inventors: W. Neal Burnette, Harvey R. Kaslow
  • Stable protein: phospholipid compositions and methods
    Patent number: 5874075
    Abstract: The invention relates to stable compositions of proteins and related methods wherein a protein capable of transitioning into the molten globular state is contacted with a negatively charged lipid vesicle, thereby stabilizing the protein against thermally-induced aggregation, denaturation, and loss of activity. The protein:phospholipid complex directly stabilizes the secondary and tertiary structure of the protein, and the compositions are useful in high temperature formulations and in novel delivery vehicles.
    Type: Grant
    Filed: March 31, 1995
    Date of Patent: February 23, 1999
    Assignee: Amgen Inc.
    Inventors: David Collins, Younsik Cha, David Brems
  • Anti-inflammatory CD14 polypeptides
    Patent number: 5869055
    Abstract: The invention relates to anti-inflammatory polypeptides comprising soluble CD14 related polypeptides having amino acids at position 7-10 that are different from the native sequence or having amino acids 1-14 deleted.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 9, 1999
    Assignee: Amgen, Inc.
    Inventors: Shao-Chieh Juan, Henri S. Lichenstein, Samuel D. Wright
  • Process for preparing 5-dithio-modified oligonucleotides
    Patent number: 5864031
    Abstract: The present invention provides nuclease resistant 5'-dithio-modified oligonucleotides that are useful in nucleic acid therapeutics and diagnostics. The novel modified oligonucleotides have at least one 5'-dithioate linkage, wherein both the oxygen atom at the 5'-position (5'-bridging oxygen) and at least one of the non-bridging oxygen atoms of a naturally occurring phosphodiester linkage are independently replaced with a single sulfur atom. The invention also provides a polymer-supported method for making 5'-dithio-modified and 5'-thio-modified oligonucleotides as well as novel monomeric nucleoside and nucleotide intermediates useful in the synthetic method.
    Type: Grant
    Filed: July 29, 1994
    Date of Patent: January 26, 1999
    Assignee: Amgen Inc.
    Inventors: Sandra E. Russo-Rodriguez, Tepper M. Koga
  • Diagnostic kits for detection of target nucleic acid sequences
    Patent number: 5863732
    Abstract: The present invention makes possible the catalytic production of sequence specific oligonucleotides through the use of a specially designed template sequence. The reaction can be made to proceed isothermally in the presence of an excess of nucleoside triphosphates, an agent for polymerization, and a cutting agent. Because the process is catalytic with respect to the template sequence, an unlimited amount of oligonucleotide product can theoretically be generated from a single molecule of template. Where the process is initiated by the presence of a nucleic acid target sequence, the method of the present invention can be used for diagnostic purposes as an amplification method to improve sensitivity. Diagnostic sensitivity can be further enhanced by employing a cascade of these template sequences.
    Type: Grant
    Filed: December 18, 1996
    Date of Patent: January 26, 1999
    Assignee: Amgen Inc.
    Inventor: Rodney M. Richards
  • Neurogene
    Patent number: 5859197
    Abstract: Disclosed are DNA and amino acid sequences for a novel polypeptide termed Neuritin which is expressed primarily in selected regions of the brain.
    Type: Grant
    Filed: October 9, 1997
    Date of Patent: January 12, 1999
    Assignees: Amgen Inc., Yeda Research & Development Co, Ltd.
    Inventors: Lars E. Theill, Gregory S. Naeve, Yoav Citri, deceased
  • Erythropoietin isoforms
    Patent number: 5856298
    Abstract: Erythropoietin isoforms having a specific number of sialic acids per erythropoietin molecule are disclosed. Also disclosed are mixtures of such isoforms, pharmaceutical compositions containing such isoforms or mixtures thereof and methods of obtaining the erythropoietin isoforms.
    Type: Grant
    Filed: November 3, 1994
    Date of Patent: January 5, 1999
    Assignee: Amgen Inc.
    Inventor: Thomas Wayne Strickland
  • Method for the treatment of Schwann cells in vivo
    Patent number: 5849705
    Abstract: Schwann cells can be treated in vivo to survive longer and to proliferate by contacting them with peptides derived from the EGF-like domain of proteins of the NDF/heregulin family.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: December 15, 1998
    Assignee: Amgen Inc.
    Inventors: Josette Francoise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer
  • Method for purifying granulocyte colony stimulating factor
    Patent number: 5849883
    Abstract: Processes for isolating and purifying granulocyte colony stimulating factor (G-CSF) from a G-CSF producing microorganism are disclosed. The simplified processes include steps of lysing the microorganism and separating insoluble material containing G-CSF from soluble proteinaceous material; extracting the material with deoxycholate (optionally); solubilizing and oxidizing the G-CSF in the presence of a denaturant solubilizing agent and an oxidizing agent; removing the denaturant solubilizing agent from the G-CSF; subjecting the G-CSF to ion exchange chromatography; and recovering the purified G-CSF; yet excludes other cumbersome purification steps.
    Type: Grant
    Filed: May 9, 1996
    Date of Patent: December 15, 1998
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Allan L. Miller, Jeffrey W. Andresen
  • Osteoprotegerin binding proteins
    Patent number: 5843678
    Abstract: A novel polypeptide, osteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget's disease are also provided.
    Type: Grant
    Filed: April 16, 1997
    Date of Patent: December 1, 1998
    Assignee: Amgen Inc.
    Inventor: William J. Boyle
  • Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
    Patent number: 5837681
    Abstract: The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear hair cells and spiral ganglion neurons by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates more specifically to methods for treating sensorineural hearing loss.
    Type: Grant
    Filed: February 23, 1996
    Date of Patent: November 17, 1998
    Assignee: Amgen Inc.
    Inventor: Ella Magal
  • Use of the human interferon consensus gene for gene therapy
    Patent number: 5831062
    Abstract: The present invention relates generally to a human interferon consensus gene useful for expression in eucaryotic systems and gene therapy. In particular, the present invention relates to treatment of cancer and cell proliferation disorders through use of viral vectors to deliver and express the human interferon consensus gene in the cells and/or tumors of a patient.
    Type: Grant
    Filed: May 8, 1997
    Date of Patent: November 3, 1998
    Assignee: Amgen Inc.
    Inventors: Milton W. Taylor, Lawrence M. Blatt
  • Eck receptor ligands
    Patent number: 5824303
    Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: October 20, 1998
    Assignee: Amgen Inc.
    Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker
  • Therapeutic uses of keratinocyte growth factor
    Patent number: 5824643
    Abstract: Based on extensive in vivo studies in animals, it has now been discovered that KGF stimulates proliferation, growth and differentiation in various cells of epithelial tissue, besides keratinocytes. This better understanding of the biological effects of KGF in vivo enables the use of this polypeptide as a therapeutic agent, suitably formulated in a pharmaceutical composition, for the specific treatment of disease states and medical conditions afflicting tissues and organs such as the dermal adnexae, the liver, the lung, and the gastrointestinal tract.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 20, 1998
    Assignee: Amgen Inc.
    Inventors: Glenn Francis Pierce, Regina Mae Housley, Charles Frederick Morris